^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Angiopoietin 2 inhibitor

    Related drugs:
    1d
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=388, Completed, Genentech, Inc. | Trial completion date: Apr 2027 --> Jun 2026 | Trial primary completion date: Apr 2027 --> May 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    15d
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    23d
    Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov)
    P4, N=100, Enrolling by invitation, University of Colorado, Denver | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    1m
    Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR • Real-world evidence
    1m
    Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Sun Yat-sen University
    New trial
    2ms
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    2ms
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=546, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    2ms
    Target Trial Emulation Framework for Comparing Early Efficacy of Faricimab and Aflibercept In the Treatment of Patients With Neovascular Age-Related Macular Degeneration With Pigment Epithelium Detachment (ChiCTR2600118980)
    P=N/A, N=97, Zhongshan Hospital, Fudan University; Zhongshan Hospital Fudan University
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    GLIA-MAC: Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Federico II University
    New trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Osijek University Hospital
    New trial
    3ms
    MAGIC: Safety and Efficacy of Faricimab in Patients With NPDR (clinicaltrials.gov)
    P2, N=179, Completed, Greater Houston Retina Research | Active, not recruiting --> Completed
    Trial completion
    3ms
    JADE: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (clinicaltrials.gov)
    P1, N=164, Completed, Ollin Biosciences, Inc.
    New P1 trial